Study of targeted radiation for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be estrogen receptor-positive (ER+) and HER2-negative, and it has spread or cannot be removed with surgery.
- You need to have adequate kidney, liver, and blood cell function.
- Depending on the study group, you must have tried certain prior treatments (like chemotherapy or CDK4/6 inhibitors).
- Your cancer must show the targeted protein on imaging tests (SSTR-PET).
- If you have bone-only or bone-dominant disease, you can join the combination group, but you cannot have liver metastases or symptomatic organ disease.
- You cannot have had prior radiopharmaceutical therapy (like radioembolization).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding a very focused type of radiation to standard drug treatment can better control metastatic breast cancer. It is for people whose cancer is only progressing in one spot, seen on a PET scan.
This study tests whether giving focused radiation (SABR) to a few growing spots of breast cancer, while continuing your current hormone therapy and CDK 4/6 inhibitor, can help control the cancer longer than switching to a different treatment. It is for people whose cancer is mostly stable but has a small number of spots that have started to grow.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.